ArriVent BioPharma

(NASDAQ) AVBP

Current Price$30.11

Market Cap$1.39B

Since IPO (2024)+50%

5 YearN/A

1 Year+42%

1 Month+24%

ArriVent BioPharma Financials at a Glance

Market Cap

$1.39B

Revenue (TTM)

$0.00

Net Income (TTM)

$166.31M

EPS (TTM)

$-4.46

P/E Ratio

-6.72

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$30.11

Volume

13,575

Open

$30.98

Price

$30.11

Volume

13,575

Open

$30.98

Previous Close

$30.11

Daily Range

$29.57 - $30.98

52-Week Range

$16.10 - $32.14

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$30.11

Volume

13,575

Open

$30.98

Previous Close

$30.11

Daily Range

$29.57 - $30.98

52-Week Range

$16.10 - $32.14

AVBP News

ArriVent Posts Wider Loss in Fiscal Q2

Motley Fool Markets TeamAug 11, 2025

AVBP: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ArriVent BioPharma

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Zheng Bin Yao, PhD

Website

www.arrivent.com

Headquarters

Newtown Square, 19073, US

AVBP Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-59%

Return on Capital

-58%

Return on Assets

-50%

Earnings Yield

-14.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.39B

Shares Outstanding

46.37M

Volume

13.57K

Avg. Volume

530.41K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$177.53M

EBITDA

$177.53M

Operating Cash Flow

$160.59M

Capital Expenditure

$0.00

Free Cash Flow

$160.59M

Cash & ST Invst.

$312.82M

Total Debt

$14.00K

ArriVent BioPharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.39B

N/A

Market Cap/Employee

$26.74M

N/A

Employees

N/A

Net Income

$35.54M

-72.3%

EBITDA

$38.82M

-63.8%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$312.81M

+43.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$14.00K

-91.4%

Return on Assets

-49.92%

N/A

Return on Invested Capital

-57.79%

N/A

Free Cash Flow

$30.66M

-89.8%

Operating Cash Flow

$30.66M

-89.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IOVAIovance Biotherapeutics, Inc.

IOVAIovance Biotherapeutics, Inc.$3.40+1.19%

MBXMBX Biosciences, Inc. Common Stock

MBXMBX Biosciences, Inc. Common Stock$29.78-1.46%

MGTXMeiraGTx Holdings plc

MGTXMeiraGTx Holdings plc$9.41+2.06%

ARVNArvinas, Inc.

ARVNArvinas, Inc.$10.51+6.16%

DNAGinkgo Bioworks Holdings, Inc.

DNAGinkgo Bioworks Holdings, Inc.$9.70+14.66%

DAWNDay One Biopharmaceuticals, Inc.

DAWNDay One Biopharmaceuticals, Inc.$21.53+0.00%

VALNValneva SE

VALNValneva SE$5.35-0.56%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

NIONio

NIONio$5.91-0.08%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$50.22-0.03%

RIVNRivian Automotive

RIVNRivian Automotive$15.02-0.08%

Questions About AVBP

What is the current price of ArriVent BioPharma?

ArriVent BioPharma is trading at $30.11 per share.

What is the 52-week range for ArriVent BioPharma?

Over the past 52 weeks, ArriVent BioPharma has traded between $16.10 and $32.14.

How much debt does ArriVent BioPharma have?

As of the most recent reporting period, ArriVent BioPharma reported total debt of $14,000.

How much cash does ArriVent BioPharma have on hand?

ArriVent BioPharma reported $45.54M in cash and cash equivalents in its most recent financial results.

What is ArriVent BioPharma’s dividend yield?

ArriVent BioPharma does not currently have a dividend yield.

ArriVent BioPharma

ArriVent BioPharma Financials at a Glance

AVBP News

ArriVent Posts Wider Loss in Fiscal Q2

AVBP: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ArriVent BioPharma

AVBP Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ArriVent BioPharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AVBP

What is the current price of ArriVent BioPharma?

What is the 52-week range for ArriVent BioPharma?

How much debt does ArriVent BioPharma have?

How much cash does ArriVent BioPharma have on hand?

What is ArriVent BioPharma’s dividend yield?

Premium Investing Services